BIIB - NASDAQ

Biogen Inc.

BIIB·NASDAQ

$195.96

+3.8%

HealthcareDrug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$28.93B

EPS8.8500

P/E Ratio22.14

Earnings Date07/30/2026

29.44B

Assets

3Y+20.0%

5Y+20.0%

10Y+29.0%

11.18B

Total Liabilities

-1%

3Y-

5Y-20.0%

10Y+4.0%

18.26B

Total Equity

3Y+36.0%

5Y+71.0%

10Y+51.0%

Biogen Inc. Funding & Solvency Profile

BIIB · NASDAQ

Current Assets

Cash & Cash Equivalents3.01B

Net Receivables1.87B

Inventory2.17B

Other Current Assets1.12B

Total Current Assets9 B

Non-Current Assets

Property, Plant & Equipment3.32B

Goodwill & Intangible Assets15.67B

Long-Term Investments750.60M

Other Non-Current Assets431.90M

Total Non-Current Assets5 B

Total Assets

29.44B

Financial Health Analysis

Current Ratio

2.68x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.61x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

6 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

30% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Biogen Inc. Balance Sheet

BIIB • NASDAQ

Biogen Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3B	2.4B	1B	3.4B	2.3B	1.3B	2.9B	1.2B	1.6B	2.3B	1.3B	1.2B	602.6M	570.7M	514.5M	759.6M	581.9M	622.4M	659.7M	661.4M
Short-Term Investments	807.2M	0.0	0.0	1.5B	1.5B	1.3B	1.6B	2.3B	2.1B	2.6B	2.1B	640.5M	620.2M	1.1B	1.2B	448.1M	681.8M	749M	523.8M	241.3M
Cash & Short-Term Investments	3.8B	2.4B	1B	4.9B	3.8B	2.6B	4.5B	3.5B	3.7B	4.9B	3.4B	1.8B	1.2B	1.7B	1.7B	1.2B	1.3B	1.4B	1.2B	902.7M
Net Receivables	1.9B	1.9B	2.1B	2.1B	2B	2.3B	2.5B	2.5B	2.3B	1.7B	1.5B	1.6B	1.1B	955.2M	831.2M	840M	760.9M	667.1M	595.7M	539.4M
Accounts Receivables	1.9B	1.9B	2.1B	2.1B	2B	2.3B	2.5B	2.5B	2.3B	1.7B	1.5B	1.6B	1.1B	955.2M	813.3M	827.8M	745M	653.6M	559.3M	486.1M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.9M	12.2M	15.9M	13.5M	36.4M	53.3M
Inventory	2.2B	2.5B	2.5B	1.3B	1.4B	1.1B	804.2M	929.9M	902.7M	1B	893.4M	804M	659M	447.4M	326.8M	289.1M	294M	263.6M	234M	169.1M
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	0.0	271.2M	657.6M	817M	550.6M	0.0	0.0	0.0	0.0	69.3M	52.6M	46.4M	33.6M	30.9M
Other Current Assets	1.1B	752.5M	1.2B	1.4B	740.8M	881.1M	631M	687.6M	304.4M	276.3M	286.3M	447.5M	226.1M	136M	144.6M	134.3M	109.4M	109.5M	321.6M	70.5M
Total Current Assets	9B	7.5B	6.9B	9.8B	7.9B	6.9B	8.4B	7.6B	7.9B	8.7B	6.7B	4.7B	3.2B	3.2B	3B	2.5B	2.5B	2.5B	2.4B	1.7B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.3B	3.5B	3.7B	3.7B	3.8B	3.8B	3.7B	3.6B	3.2B	2.5B	2.2B	1.8B	1.8B	1.7B	1.6B	1.6B	1.6B	1.6B	1.5B	1.3B
Goodwill	6.5B	6.5B	6.2B	5.7B	5.8B	5.8B	5.8B	5.7B	4.6B	3.7B	2.7B	1.8B	1.2B	1.2B	1.1B	1.1B	1.1B	1.1B	1.1B	1.2B
Intangible Assets	9.2B	9.7B	8.4B	1.9B	2.2B	3.1B	3.5B	3.1B	3.9B	3.8B	4.1B	4B	4.5B	1.6B	1.6B	1.8B	1.9B	2.2B	2.5B	2.7B
Goodwill & Intangible Assets	15.7B	16.2B	14.6B	7.6B	8B	8.8B	9.3B	8.8B	8.5B	7.5B	6.7B	5.8B	5.7B	2.8B	2.8B	2.9B	3B	3.3B	3.6B	3.9B
Long-Term Investments	750.6M	226.7M	0.0	705.7M	892M	772.1M	1.4B	1.4B	3.1B	2.8B	2.8B	1.5B	625.8M	2B	1.4B	991.3M	1.4B	1.1B	1.1B	1.7B
Tax Assets	292.5M	324.2M	928.6M	1.2B	1.4B	1.4B	3.2B	2.2B	595.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	431.9M	333.8M	745M	1.5B	1.9B	2.9B	1.3B	1.7B	431.6M	1.3B	1.1B	754.6M	594.4M	274.1M	331.5M	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	20.5B	20.6B	20B	14.8B	16B	17.7B	18.9B	17.6B	15.8B	14.1B	12.8B	9.6B	8.7B	6.9B	6.1B	5.6B	6.1B	6B	6.3B	6.8B
Total Assets	29.4B	28B	26.8B	24.6B	23.9B	24.6B	27.2B	25.3B	23.7B	22.9B	19.5B	14.3B	11.9B	10.1B	9B	8.1B	8.6B	8.5B	8.6B	8.6B
LIABILITIES
CURRENT LIABILITIES
Total Payables	546.8M	972.5M	660.7M	751.4M	763.9M	596.9M	602.2M	434M	463.7M	511.7M	476.1M	397.3M	399.6M	224.1M	232.4M	247M	194.4M	360.7M	310.2M	246M
Accounts Payable	432M	424.2M	403.3M	491.5M	589.2M	454.9M	530.8M	370.5M	395.5M	279.8M	267.4M	229.2M	219.9M	204M	186.4M	162.5M	118.5M	107.4M	90.7M	100.5M
Other Payables	114.8M	548.3M	257.4M	259.9M	174.7M	142M	71.4M	63.5M	68.2M	231.9M	208.7M	168.1M	179.7M	20.1M	45.9M	84.5M	75.9M	253.3M	219.5M	145.5M
Accrued Expenses	0.0	2.4B	2.3B	1.4B	2.2B	2.6B	2.5B	2.5B	2.6B	2.6B	1.8B	1.3B	839.1M	583.4M	431.3M	464.9M	335M	378.9M	367.9M	336.9M
Short Term Debt	80.4M	1.7B	150M	0.0	999.1M	0.0	1.5B	0.0	3.2M	4.7M	4.8M	3.1M	3.5M	453.4M	3.3M	137.2M	19.8M	27.7M	1.5B	0.0
Tax Payables	114.8M	548.3M	257.4M	259.9M	174.7M	142M	71.4M	63.5M	68.2M	231.9M	208.7M	168.1M	179.7M	20.1M	45.9M	84.5M	75.9M	223.3M	11.3M	145.5M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.7M	120.9M	172.7M	148M	69.6M	41.3M	38.7M	0.0	0.0	0.0
Other Current Liabilities	2.7B	375.8M	335.1M	1.1B	345.1M	515.3M	315.8M	320.9M	297.7M	282.9M	215.1M	393.8M	343.4M	248.5M	176.3M	159.7M	127.1M	156M	0.0	0.0
Total Current Liabilities	3.3B	5.5B	3.4B	3.3B	4.3B	3.7B	4.9B	3.3B	3.4B	3.4B	2.6B	2.2B	1.8B	1.7B	912.9M	1.1B	714.9M	923.2M	2.2B	582.9M
NON-CURRENT LIABILITIES
Long Term Debt	6.6B	4.5B	6.8B	6.3B	6.3B	7.4B	4.5B	5.9B	5.9B	6.5B	6.5B	580.3M	592.4M	687.4M	1.1B	1.1B	1.1B	1.1B	51.8M	96.7M
Deferred Tax Liabilities (Non-Current)	507.6M	190.5M	641.8M	334.7M	694.5M	1B	2.8B	1.6B	122.6M	93.1M	124.9M	50.7M	232.6M	217.3M	248.6M	201M	240.6M	356M	521.5M	643.6M
Other Non-Current Liabilities	458.1M	732.3M	781.1M	944.2M	1.3B	1.3B	1.3B	1.4B	1.6B	722.5M	905.8M	650.1M	659.2M	604.3M	400.3M	325.6M	254.2M	308.2M	332M	79.8M
Total Non-Current Liabilities	7.8B	5.8B	8.6B	7.9B	8.6B	10.2B	9B	9B	7.7B	7.3B	7.6B	1.3B	1.5B	1.5B	1.7B	1.6B	1.6B	1.7B	905.3M	820.2M
Capital Lease Obligations	290.4M	334.5M	400M	333M	330.4M	402M	412.7M	0.0	0.0	16.4M	18.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	11.2B	11.3B	12B	11.2B	12.9B	13.9B	13.9B	12.3B	11.1B	10.7B	10.1B	3.5B	3.2B	3.2B	2.6B	2.6B	2.3B	2.7B	3.1B	1.4B
SHAREHOLDERS' EQUITY
Treasury Stock	-3B	-3B	-3B	-3B	-3B	-3B	-3B	-3B	-3B	-2.6B	-2.6B	-2.6B	-1.7B	-1.3B	-839.9M	-349.6M	-679.9M	-527.1M	0.0	-319.7M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	5M	596K	2.3M	1.5M	0.0	0.0	0.0	0.0	0.0
Common Stock	100K	100K	100K	100K	100K	100K	100K	100K	100K	100K	100K	129K	128K	127K	128K	124K	144K	149K	147K	173K
Additional Paid-In Capital	863.1M	569.4M	302.5M	73.3M	68.2M	0.0	0.0	0.0	97.8M	0.0	0.0	4.2B	4B	3.9B	4.2B	3.9B	5.8B	6.1B	5.8B	8.3B
Retained Earnings	20.6B	19.3B	17.6B	16.5B	13.9B	14B	16.5B	16.3B	15.8B	15.1B	12.2B	9.3B	6.3B	4.5B	3.1B	1.9B	1.1B	270.2M	-352.2M	-860.8M
Accumulated Other Comprehensive Income/Loss	-182M	-136.2M	-153.7M	-164.9M	-106.7M	-299M	-135.2M	-240.4M	-318.4M	-319.9M	-224M	-59.5M	-27.7M	-55.3M	-26.5M	-21.6M	50.5M	-11.1M	79.2M	21.9M
Total Stockholders' Equity	18.3B	16.7B	14.8B	13.4B	10.9B	10.7B	13.3B	13B	12.6B	12.1B	9.4B	10.8B	8.6B	7B	6.4B	5.4B	6.2B	5.8B	5.5B	7.1B
Total Equity	18.3B	16.7B	14.8B	13.4B	11B	10.7B	13.3B	13B	12.6B	12.1B	9.4B	10.8B	8.6B	7B	6.4B	5.4B	6.3B	5.8B	5.5B	7.1B
Minority Interest	0.0	0.0	0.0	-9.5M	63.5M	-14.2M	-4.1M	-8M	-14.7M	-11.5M	2.1M	5M	596K	2.3M	1.5M	52.9M	40.4M	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	29.4B	28B	26.8B	24.6B	23.9B	24.6B	27.2B	25.3B	23.7B	22.9B	19.5B	14.3B	11.9B	10.1B	9B	8.1B	8.6B	8.5B	8.6B	8.6B
Total Investments	1.6B	226.7M	0.0	2.2B	2.4B	2.1B	3B	3.7B	5.2B	5.4B	4.9B	2.1B	1.2B	3.2B	2.6B	1.4B	2.1B	1.9B	1.7B	1.9B
Total Debt	6.9B	6.6B	7.3B	6.6B	7.6B	7.8B	6.4B	5.9B	5.9B	6.5B	6.5B	585.2M	595.9M	1.1B	1.1B	1.2B	1.1B	1.1B	1.6B	96.7M
Net Debt	3.9B	4.3B	6.3B	3.2B	5.3B	6.5B	3.5B	4.7B	4.4B	4.2B	5.2B	-621.5M	-6.6M	570.1M	549.6M	443.9M	518.1M	490.7M	903.3M	-564.7M
Shares Outstanding	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272	146,702,272

SEC Filings

BIIB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 29, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	April 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 06, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 06, 2026	February 06, 2026	2026	View Filing

Showing 1 to 10 of 464 filings

Related Guides

Blog Categories

Continue your BIIB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.